Liver fibrosis inhibits lethal injury through D-galactosamine/lipopolysaccharide-induced necroptosis.
10.3760/cma.j.cn501113-20201204-00639
- Author:
Lu LI
1
;
Li BAI
2
,
3
;
Su Jun ZHENG
4
;
Yu CHEN
2
,
3
;
Zhong Ping DUAN
2
,
3
Author Information
1. Department of Infectious Diseases, Peking University Third Hospital, Beijing 100191, China.
2. Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research
3. The Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China.
4. The First Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Chemical and Drug Induced Liver Injury/pathology*;
Galactosamine/adverse effects*;
Lipopolysaccharides/adverse effects*;
Liver/pathology*;
Liver Cirrhosis/pathology*;
Liver Failure, Acute/chemically induced*;
Mice;
Necroptosis
- From:
Chinese Journal of Hepatology
2022;30(4):413-418
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the new mechanism of liver fibrosis through D-galactosamine/lipopolysaccharide (D-GalN/LPS)-induced necroptosis as an entry point to inhibit lethal injury. Methods: The carbon tetrachloride (CCl4)-induced mouse model of liver fibrosis was established. At 6 weeks of fibrosis, the mice were challenged with a lethal dose of D-GalN/LPS, and the normal mice treated with the same treatment were used as the control. The experiment was divided into four groups: control group (Control), acute injury group (D-GalN/LPS), liver fibrosis group (Fib), and liver fibrosis + acute challenge group (Fib + D-GalN/LPS). Quantitative PCR and immunofluorescence were used to analyze the expression of necroptosis key signal molecules RIPK1, RIPK3, MLKL and/or P-MLKL in each group. Normal mice were treated with inhibitors targeting key signaling molecules of necroptosis, and then given an acute challenge. The inhibitory effect of D-GalN/LPS-induced-necroptosis on acute liver injury was evaluated according to the changes in transaminase levels and liver histology. Liver fibrosis spontaneous ablation model was established, and then acute challenge was given. Necroptosis key signal molecules expression was analyzed in liver tissue of mice in each group and compared by immunohistochemistry. The differences between groups were compared with t-test or analysis of variance. Results: Quantitative PCR and immunofluorescence assays result showed that D-GalN/LPS-induced significant upregulation of RIPK1, RIPK3, MLKL and/or P-MLKL. Necroptosis key signal molecules inhibition had significantly reduced D-GalN/LPS-induced liver injury, as manifested by markedly reduced serum ALT and AST levels with improvement in liver histology. Necroptosis signaling molecules expression was significantly inhibited in fibrotic livers even under acute challenge conditions. Additionally, liver fibrosis with gradual attenuation of fibrotic ablation had inhibited D-GalN/LPS-induced necroptosis. Conclusion: Liver fibrosis may protect mice from acute lethal challenge injury by inhibiting D-GalN/LPS-induced necroptosis.
